The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Natural History of Untreated Nonsurgical Hepatocellular Carcinoma: Rationale for the Design and Evaluation of Therapeutic Trials
Abstract
This study analyzed the natural history and prognostic factors of patients with nonsurgical hepatocellular carcinoma (HCC). Twenty variables from 102 cirrhotic patients with HCC who were not treated within prospective randomized controlled trials (RCT) were investigated through uni– and multivariate analyses. None of them was suitable for radical therapies (surgical resection, liver transplantation, or ethanol injection) or presented end–stage disease as reflected by an Okuda stage 3 or a Performance Status ≥3. Sixty–five patients were Child–Pugh A, 34 were B, and 3 were C. Most of them exhibited a preserved Performance Status Test (PST) (0 = 56; 1 = 38; 2 = 8). Tumor was solitary in 26 (≤5 cm in 16) and multinodular/massive in 76. After a median follow–up of 17 months, 79 patients died, the 1–, 2–, and 3–year survival being 54%, 40%, and 28%. The multivariate study identified PST (P = .01), constitutional syndrome (P = .04), vascular invasion (P = .001), and extrahepatic spread (P = .04) as independent predictors for mortality. The 1–, 2–, and 3–year survival for the 48 patients without adverse factors (Stage 0) was 80%, 65%, and 50%, respectively, and 29%, 16%, and 8% in the 54 patients with at least one adverse parameter (Stage I). Therefore, Stage 0 would correspond to an intermediate stage, while Stage I would represent an advanced status, before reaching an end–stage phase. In conclusion, the outcome of nonsurgical HCC is not homogeneously grim and may be predicted by assessing the presence of symptoms and of an invasive tumoral pattern. Therapeutic trials should be designed and evaluated considering these characteristics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transection of the oesophagus for bleeding oesophageal varices
Pugh, R. N. H., Murray-Lyon, I. M., Dawson, J. L., Pietroni, M. C., & Williams, R. (1973) · Journal of British Surgery · doi:10.1002/bjs.1800600817 · Cited by 7,941
Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., Montalto, F., Ammatuna, M., Morabito, A., & Gennari, L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603143341104 · Cited by 7,186
Okuda, K., Ohtsuki, T., Obata, H., Tomimatsu, M., Okazaki, N., Hasegawa, H., Nakajima, Y., & Ohnishi, K. (1985) · Cancer · doi:10.1002/1097-0142(19850815)56:4<918::aid-cncr2820560437>3.0.co;2-e · Cited by 1,931
The treatment of portal hypertension: A meta-analytic review
D'amico, G., Pagliaro, L., & Bosch, J. (1995) · Hepatology · doi:10.1002/hep.1840220145 · Cited by 1,015
Bruix, J., Castells, A., Bosch, J., Feu, F., Fuster, J., Garcia-Pagan, J., Visa, J., Bru, C., & Rodes, J. (1996) · Gastroenterology · doi:10.1016/s0016-5085(96)70070-7 · Cited by 895
Self-citation(1995) · New England Journal of Medicine · doi:10.1056/nejm199505113321903 · Cited by 809
Bruix, J., Llovet, J. M., Castells, A., Montañá, X., Brú, C., Ayuso, M. D. C., Vilana, R., & Rodés, J. (1998) · Hepatology · doi:10.1002/hep.510270617 · Cited by 533
Self-citationPerformance status assessment in cancer patients. An inter-observer variability study
Sørensen, J., Klee, M., Palshof, T., & Hansen, H. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.140 · Cited by 483
Barbara, L., Benzi, G., Gaiani, S., Fusconi, F., Zironi, G., Siringo, S., Rigamonti, A., Barbara, C., Grigioni, W., Mazziotti, A., et al. (1992) · Hepatology · doi:10.1002/hep.1840160122 · Cited by 431
Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications
Sheu, J.-C., Sung, J.-L., Chen, D.-S., Yang, P.-M., Lai, M.-Y., Lee, C.-S., Hsu, H.-C., Chuang, C.-N., Yang, P.-C., Wang, T.-H., et al. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90324-5 · Cited by 427
Ebara, M., Ohto, M., Shinagawa, T., Sugiura, N., Kimura, K., Matsutani, S., Morita, M., Saisho, H., Tsuchiya, Y., & Okuda, K. (1986) · Gastroenterology · doi:10.1016/0016-5085(86)90923-6 · Cited by 394
Llovet, J. M., Bruix, J., Fuster, J., Castells, A., Garcia-Valdecasas, J. C., Grande, L., França, A., Brú, C., Navasa, M., Ayuso, M. D., et al. (1998) · Hepatology · doi:10.1002/hep.510270616 · Cited by 382
Self-citationTreatment of hepatocellular carcinoma: A systematic review of randomized controlled trials
Simonetti, R. G., Liberati, A., Angiolini, C., & Pagliaro, L. (1997) · Annals of Oncology · doi:10.1023/a:1008285123736 · Cited by 380
Castells, A., Bruix, J., Bru, C., Fuster, J., Vilana, R., Navasa, M., Ayuso, C., Boix, L., Visa, J., & Rodés, J. (1993) · Hepatology · doi:10.1002/hep.1840180517 · Cited by 368
Self-citationHepatocellular carcinoma in the United States: Prognostic features, treatment outcome, and survival
Stuart, K. E., Anand, A. J., & Jenkins, R. L. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960601)77:11<2217::aid-cncr6>3.0.co;2-m · Cited by 354
Nomura, F., Ohnishi, K., & Tanabe, Y. (1989) · Cancer · doi:10.1002/1097-0142(19891015)64:8<1700::aid-cncr2820640824>3.0.co;2-z · Cited by 305
Livraghi, T., Bolondi, L., Buscarini, L., Cottone, M., Mazziotti, A., Morabito, A., & Torzilli, G. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80445-5 · Cited by 278
Treatment of Hepatocellular Carcinoma
Bruix, J. (1997) · Hepatology · doi:10.1002/hep.510250201 · Cited by 277
Self-citationVilana, R., Bruix, J., Bru, C., Ayuso, C., Solé, M., & Rodés, J. (1992) · Hepatology · doi:10.1002/hep.1840160212 · Cited by 270
Self-citationPrognostic factors of hepatocellular carcinoma in the west: A multivariate analysis in 206 patients
Calvet, X., Bruix, J., Ginés, P., Bru, C., Sole, M., Vilana, R., & Rodés, J. (1990) · Hepatology · doi:10.1002/hep.1840120422 · Cited by 226
Self-citationCastells, A., Bruix, J., Brú, C., Ayuso, C., Roca, M., Boix, L., Vilana, R., & Rodés, J. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90402-6 · Cited by 187
Self-citationArroyo, V., Ginès, P., Rimola, A., & Gaya, J. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90912-5 · Cited by 140
Natural history of hepatocellular carcinoma in Spain
Calvet, X., Bruix, J., Brú, C., Ginès, P., Vilana, R., Solé, M., Ayuso, M. D. C., Bruguera, M., & Rodés, J. (1990) · Journal of Hepatology · doi:10.1016/0168-8278(90)90138-h · Cited by 124
Self-citationAsymptomatic hepatocellular carcinoma in Child's A cirrhosis
Cottone, M., Virdone, R., Fusco, G., et al. (1989) · Gastroenterology · doi:10.1016/0016-5085(89)90528-3 · Cited by 116
Burroughs, A. K. (1995) · UCL Discovery (University College London) · Cited by 35
Cited by
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Galle, P. R., Forner, A., Llovet, J. M., Mazzaferro, V., Piscaglia, F., Raoul, J.-L., Schirmacher, P., & Vilgrain, V. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.03.019 · Cited by 11,406
Self-citationLlovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
Self-citationManagement of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,857
Self-citationCheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
European Association for the Study of the Liver, & European Organisation for Research and Treatment of Cancer (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.12.001 · Cited by 5,218
“Analysis of heterogeneous outcomes within 25 RCT (2 year survival 8–50%) [131,133,139,163] HCC”
Background
Metadata
- Authors
- Llovet, J. M., Bustamante, J., Castells, A., Vilana, R., Del Carmen Ayuso, M., Sala, M., Brú, C., Rodés, J., & Bruix, J.
- Venue
- Hepatology
- Published
- 1999-01
- Volume
- 29
- Issue
- 1
- Pages
- 62-67
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2163557371
- Cited by
- 1,190
- References
- 25
- FWCI
- 13.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.